ReviewOpen heart2025
Technology for better adult congenital heart disease care: the time is now.
Review in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe growing population of patients with adult congenital heart disease (ACHD) present complex lifelong care needs that traditional health systems are struggling to meet. Without innovation, gaps in access, timeliness and specialist oversight will widen. Digital health technologies, including artificial intelligence (AI), telemedicine, wearable devices and interoperable platforms offer a unique opportunity to transform care, but their potential in ACHD remain underexplored. CURRENT DEVELOPMENTS: AI-driven prediction models show encouraging performance in mortality and event risk but require external validation and lesion-specific adaptation. Telemedicine, accelerated during the COVID-19 pandemic, has demonstrated safety and high patient satisfaction in selected cohorts, yet robust hybrid pathways are lacking. Wearables can capture rhythm, oxygen saturations and activity in real time, but consumer devices remain poorly validated for complex ACHD physiology. Data integration frameworks, such as federated learning, demonstrate global feasibility but face challenges in governance and interoperability. FUTURE PRIORITIES: Progress in ACHD digital health will depend on three imperatives: (1) rigorous, prospective validation of digital tools in congenital populations; (2) equitable implementation, addressing digital literacy, infrastructure and reimbursement; (3) governance frameworks that embed specialist oversight, data privacy and cybersecurity from the outset.
conclusionDigital health is no longer optional in ACHD care. The field risks falling behind broader cardiovascular innovation unless patients, clinicians, technologists and policymakers commit to specialist-led integration. A decisive shift towards validated, equitable and interoperable solutions can transform ACHD management into a more predictive, personalised and preventive discipline. The aim of this viewpoint is to highlight how digital technologies could strengthen ACHD care and define priorities for future adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.